Open-label, Randomized, 2-way Crossover, Monocentric, Controlled Study to Evaluate the Effect on Daily PHE Fluctuation of PKU GOLIKE Versus SoC in Patients With PKU.

NCT ID: NCT05827536

Last Updated: 2024-08-01

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-30
• Study Completion Date: 2024-12-31

Brief Summary

This is an open-label, randomized, 2-way crossover, monocentric controlled study in patients (≥ 16 years old) with phenylketonuria (PKU).

The comparison will be between the test product (PKU GOLIKE, a prolonged-release amino-acids (AAs) mixture) and standard of care.

Detailed Description

The study will consist of a screening visit (V1), two treatment periods with two test days each and a final visit planned at the end of the second treatment period (V2). Test days will occur on two consecutive preferably non-working/school days (T1-T2 and T3-T4,) preferably over two consecutive weeks. Treatment days in the two periods will have to be the same days of the week. T1 should be within two weeks after V1. The study products will be self-administered at home. Following informed consent and verification of eligibility criteria, 20 patients with PKU will be randomized in a 1:1 ratio to one of the following two sequences: AB or BA where A=standard of care and B=PKU GOLIKE. In details:

• AB: patients will receive 3 daily self-administrations of their usual standard of care for 2 consecutive days in the first period followed by 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in thesecond period.
• BA: patients will receive 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the first period followed by 3 daily self administrations of their usual standard of care for 2 consecutive days in the second period.

No change in the randomization sequence will be allowed.

Each patient will follow the same diet in terms of food, calories and nutrients ranges during the first days (T1 and T3) of each period and the same diet during the second days (T2 and T4) of each period, according to the age and body weight of the patient. The days before the test days each patient will follow her/his standard diet.

PKU GOLIKE /standard of care will be the only protein substitute allowed on each test day, and no sports activities will be allowed on sampling days. Five blood spots will be collected on the second test day of each period. Timing of self-administrations, meals and blood spots will be standardized for each test day. On the test days, no food will be allowed outside of the defined time windows. The first self-administration of each test day will be performed after an overnight fasting (10 -12 h) and before any food intake.

A patient's e-diary will be used to collect information on patient compliance, 24-hour blood spot collections, diet, daily activities, adverse events and event-related concomitant medications.

Adverse events will be continuously monitored during the study, starting from informed consent. Adverse events will be collected by the patients (or by a parent/guardian) in the e-diary and during the telephone calls made by the Investigator to the patients. Moreover, patients (or parents/guardians) will be instructed to promptly report adverse events occurring during the study to the Investigator.

The end of study (V2) will be performed (remotely, by phone) at the end ofthe second treatment period, within 2 weeks after the last test day. Patients prematurely discontinued from the study will be asked to attend (remotely, by phone) a discontinuation visit possibly taking place within 2 weeks from the last test day. At the final/discontinuation visit, the investigator will organize collection of blood spots test and residual PKU GOLIKE product from the patient's domicile through a dedicated courier service. The account of the e-diary will be inactivated.

Conditions

Phenylketonurias

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AB where A=standard of care and B=PKU GOLIKE

Patients will receive 3 daily self-administrations of their usual standard of care for 2 consecutive days in the first period followed by 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the second period.

Group Type: OTHER

PKU GOLIKE

Intervention Type: DIETARY_SUPPLEMENT

PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.

Standard of Care

Intervention Type: DIETARY_SUPPLEMENT

Protein substitute

BA where B=PKU GOLIKE and A=standard of care

Patients will receive 3 daily self-administrations of PKU GOLIKE for 2 consecutive days in the first period followed by 3 daily self-administrations of their usual standard of care for 2 consecutive days in the second period.

Group Type: OTHER

PKU GOLIKE

Intervention Type: DIETARY_SUPPLEMENT

PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.

Standard of Care

Intervention Type: DIETARY_SUPPLEMENT

Protein substitute

Interventions

PKU GOLIKE

PKU GOLIKE is a food for special medicinal purposes (FSMP) for the dietary management of PKU.

Intervention Type: DIETARY_SUPPLEMENT

Standard of Care

Protein substitute

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

1. Signed, informed consent obtained by the patient prior to beingenrolled into the study and prior to starting any data collection. For legally minor patients, signed written consent shall be obtained also by the parents/legal guardian

2. Male or female, aged ≥16 years.

3. Patients with a registered diagnosis of PKU

4. Ability and willingness to comply with all study procedures and availability for the duration of the study.

5. Patients with mean value of blood Phe >360 µM in the previous 12 months (calculated on at least 3 samples during the previous 12 months; the last sample should be preferably obtained in the 30 days preceding inclusion in the study).

6. Patient taking free-AA and/or GMP as usual amino-acidssupplementation.

Exclusion Criteria

1. Known or suspected hypersensitivity to any excipients/components of PKU GOLIKE.

2. Treatment with any drug therapy for PKU

3. Patient taking PKU GOLIKE as usual amino-acids supplementation

4. Patient taking LNAA as usual amino-acids supplementation

5. Any moderate to severe medical condition, which in the opinion of the Investigator would interfere with the study procedures or study outcome (reason to be provided)

6. Any current participation in another clinical trial involving investigational or marketed products in the 3 months prior to the inclusion in this study.

7. Pregnancy or lactation.

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

APR Applied Pharma Research s.a.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Valentina Rovelli, MD

Role: PRINCIPAL_INVESTIGATOR

ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo, Via Antonio di Rudinì 8 - 20142, Milano (Italy)

Locations

ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo, Via Antonio di Rudinì 8

Milan, , Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Giorgio Reiner

Role: CONTACT

giorgio.reiner@apr.ch

+41.91.6957020

Facility Contacts

Valentina Rovelli, MD

Role: primary

valentina.rovelli@asst-santipaolocarlo.it

+390281844554

Other Identifiers

GLK-IT-2023

Identifier Type: -

Identifier Source: org_study_id